News | January 29, 2026
Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
The newly certified kits are designed for early detection and large-scale screening programs
The newly certified kits are designed for early detection and large-scale screening programs
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The plant is expected to enhance regional supply capabilities
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
